Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | PMM2 | O15305 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30333047 | 0.88 | MAPT (0.40) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL397235 | 0.79 | MAPT (0.48) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL16243453 | 0.79 | MAPT (0.48) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL16794657 | 0.78 | MAPT (0.47) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL14994629 | 0.78 | MAPT (0.47) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL25746099 | 0.77 | LMNA (0.40) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL4055908 | 0.75 | MAPT (0.44) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL20945316 | 0.75 | MAPT (0.44) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL13604348 | 0.75 | MAPT (0.44) | MAPTHTTKDM4ELMNANPSR1 | |
| SCHEMBL1197883 | 0.75 | LMNA (0.39) | MAPTHTTKDM4ELMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401964-B | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-4043462-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2022-08-17 | — | — | EP | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| CN-114401964-A | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-7884108-B2 | tyrosine kinase inhibitors such as N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-fluorophenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide for treating bone disorders, allergic disorders, autoimmune diseases, inflammatory diseases | CGI PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884108-B2 | tyrosine kinase inhibitors such as N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-fluorophenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide for treating bone disorders, allergic disorders, autoimmune diseases, inflammatory diseases | CGI PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| CN-101861307-A | Acid amides, its preparation method that replaces and be used for the treatment of for example purposes of cancer of disease | CGI PHARMACEUTICALS INC | 2010-10-13 | — | — | CN | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
| EP-1861399-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006099268-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | BRD4, BICRA, BET1 | MAPT 2296/4885HTT 1127/4885KDM4E 282/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | MAPT 4844/4885HTT 1969/4885KDM4E 444/4885 |
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | MAPT 3319/4885HTT 3057/4885KDM4E 4170/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | MAPT 3152/4885HTT 3593/4885KDM4E 1262/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | MAPT 4584/4885HTT 4719/4885KDM4E 1434/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | MAPT 4844/4885HTT 1969/4885KDM4E 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.